Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This study reports that C3H/HeJ mice and DEBR rats serve as effective models for screening potential treatments for human alopecia areata, despite certain challenges in predictability and cost.

This study suggests the existence of a new subtype of alopecia, called 'acute diffuse and total alopecia of the female scalp (ADTAFS)', characterized by acute, diffuse hair loss primarily in women and a rapid recovery.

This background review discusses alopecia areata, highlighting the role of CD8+NKG2D+ T cells in hair follicle pathogenesis, and notes that the exact mechanisms causing hair loss remain unclear.

This review highlights the challenges in treating alopecia areata, noting that current therapies often lead to relapse and have uncertain long-term effectiveness; it also points to potential future treatments such as JAK-STAT inhibitors and PRP.

This abstract does not provide specific findings or results.

This study demonstrated the expression of type 1 interferon-related proteins in inflammatory lesions of alopecia areata, showing a distinct distribution pattern compared to cicatricial alopecia.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.

This article discusses the etiology, clinical features, and treatment of alopecia areata but presents no new clinical findings, underlining the palliative nature of current therapies.

This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.

This article reviews the diagnosis and management of alopecia areata but reports no new research findings.

This review discusses the variability and limitations of treatments for severe alopecia areata, noting some patients may achieve cosmetic hair regrowth with treatment, while others experience persistent hair loss or relapse.

This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.

This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

This review discusses current and potential treatments for alopecia areata, focusing on immunosuppressive and immunomodulatory approaches, but provides no new clinical results.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

In this study, three children with severe alopecia treated with systemic tofacitinib showed significant hair regrowth, suggesting it may be a potential option for those unresponsive to conventional therapy.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

In this study, bimatoprost solution showed better results than corticosteroid in terms of rapidity, percentage of hair regrowth, and side effects for treating scalp alopecia areata.

This abstract discusses the uncertain role of the vascular system in hair loss and highlights the unexplained aspects of various types of alopecias; it reports no new research findings.

This review discusses the clinical characteristics, diagnosis, and treatment of alopecia areata, exploring potential environmental, immunological, and genetic factors involved in its development, but reports no new research findings.

Minoxidil doesn't affect perifollicular lymphoid infiltration in alopecia areata patients.

In this study, all four cases of congenital alopecia areata experienced periods of remission, with clobetasol propionate 0.05% achieving full hair regrowth in half of the patients treated.

This report examines efforts to enhance the efficacy of topical steroids for alopecia areata using penetration-enhancing vehicles and exceptionally high concentrations, noting systemic steroids often lead to relapses and toxicity.

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

This review outlines the mechanisms, clinical features, and management strategies for alopecia areata and presents no new experimental findings.

This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.

In this study, all five patients with zinc deficiency-related hair loss experienced improvement or recovery of their condition after receiving oral zinc treatment.